MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021. Updates since our last earnings release Achieved record fourth quarter revenues of $36.0 million reflecting growth of 33% compared to the prior year period and grew the Sequel II/IIe... Read more
Q4 2021 revenues $683.5M, up 8.9% year-over-year (yoy); organic revenue growth of 11.4% yoy Q4 2021 GAAP EPS $0.50; non-GAAP EPS $0.59, up $0.01 yoy FY 2021 revenues of $2.42B, up 21.7% yoy; organic revenue growth of 19.1% yoy FY 2021 GAAP EPS $1.81; non-GAAP EPS $2.10, up 55.6% yoy Solid organic revenue and non-GAAP... Read more
EUROIMMUN assay used to detect previous dengue virus infection will help children and adolescents gain access to vaccine WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 3, 2022– EUROIMMUN, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its EUROIMMUN® Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) (research use only) was cited by the U.S. Centers for Disease Control and Prevention... Read more
Full-year organic growth, adjusted EBITDA margin expansion, adjusted earnings per share in line with November guidance Full-year revenue of $5.2 billion, up 7% on a reported basis, up 4% organically Full-year reported earnings per share of $2.35, up 68%; adjusted earnings per share of $2.49, up 21% Strong demand drives continuing commercial momentum in all... Read more
FRANKLIN LAKES, N.J., Feb. 3, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. “Our first quarter results reflect continued execution of our BD2025 strategy and strong base business performance from all three segments.... Read more
WALTHAM, Mass., Feb. 2, 2022 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Full Year 2021 Highlights Fourth quarter revenue was $10.70 billion. Fourth quarter GAAP diluted earnings per share (EPS)... Read more
4Q Revenue of $1.36 billion; 1% reported growth; -9% organic growth 4Q GAAP EPS from continuing operations of $1.41; Adjusted EPS of $2.56 Initiates First Quarter and Full Year 2022 Guidance WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 1, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for... Read more
WASHINGTON, Jan. 27, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2021. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended December 31, 2021, net earnings were $1.8 billion, or $2.39 per diluted common share which represents a... Read more
Fourth quarter 2021 revenue and earnings per share to exceed prior guidance Non-COVID organic growth in fourth quarter 2021 of approximately 10% Fourth quarter 2021 COVID product and services related revenue of approximately $320 million WALTHAM, Mass.–(BUSINESS WIRE)–Jan. 11, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today... Read more
Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins WALTHAM, Mass., Jan. 5, 2022 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash... Read more